상세 보기
Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- Lee, Jung Min;
- Kim, Do Young;
- Cho, Hee Jeong;
- Moon, Joon Ho;
- Sohn, Sang Kyun;
- ... Baek, Dong Won;
- 외 5명
WEB OF SCIENCE
1SCOPUS
1초록
Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions: When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.
키워드
- 제목
- Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- 저자
- Lee, Jung Min; Kim, Do Young; Cho, Hee Jeong; Moon, Joon Ho; Sohn, Sang Kyun; Shin, Ho Jin; Do, Young Rok; Heo, Mi Hwa; Kim, Min Kyoung; Park, Young Seob; Baek, Dong Won
- 발행일
- 2025-01
- 유형
- Article
- 권
- 40
- 호
- 1
- 페이지
- 124 ~ 134
- 언어
- ENG
- 출판사
- KOREAN ASSOC INTERNAL MEDICINE
- 발행국가
- 대한민국
- 분량
- 11 페이지
- ISSN
- E 2005-6648
P 1226-3303